Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Lung Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    March 2020
  1. LEE J, Kim HS, Lee B, Kim HK, et al
    Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32809.
    PubMed     Text format     Abstract available


  2. PASSARO A, Malapelle U, Attili I, de Marinis F, et al
    Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32810.
    PubMed     Text format    


  3. PETRILLO LA, El-Jawahri A, Nipp RD, Lichtenstein MRL, et al
    Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Cancer. 2020 Mar 6. doi: 10.1002/cncr.32782.
    PubMed     Text format     Abstract available


    February 2020
  4. PRINTZ C
    New research finds lung cancer screening guidelines are insufficient for firefighters.
    Cancer. 2020;126:692-693.
    PubMed     Text format    


  5. PRINTZ C
    A more effective approach to lung cancer screening?: Researchers have developed a new risk prediction model to help inform patients and their physicians whether they should undergo lung cancer screening and, if so, when.
    Cancer. 2020;126:691-692.
    PubMed     Text format    


  6. TAKAHAMA T, Azuma K, Shimokawa M, Takeda M, et al
    Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Cancer. 2020 Feb 5. doi: 10.1002/cncr.32749.
    PubMed     Text format     Abstract available


    January 2020
  7. ZHANG H, Qian G, Zong D, Fan S, et al
    Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32744.
    PubMed     Text format     Abstract available


  8. LEUNG M, Freidin MB, Freydina DV, Von Crease C, et al
    Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer.
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32699.
    PubMed     Text format     Abstract available


  9. WEISS JM, Pennell N, Deal AM, Morgenzstern D, et al
    Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
    Cancer. 2020 Jan 14. doi: 10.1002/cncr.32573.
    PubMed     Text format     Abstract available


  10. YOUN B, Trikalinos NA, Mor V, Wilson IB, et al
    Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer.
    Cancer. 2020 Jan 14. doi: 10.1002/cncr.32624.
    PubMed     Text format     Abstract available


  11. AGGARWAL C, Langer CJ
    Systemic therapy for elderly patients with non-small cell lung cancer: Where do we stand in 2019?
    Cancer. 2020 Jan 14. doi: 10.1002/cncr.32625.
    PubMed     Text format    


    December 2019
  12. LI Y, Zang H, Qian G, Owonikoko TK, et al
    ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib.
    Cancer. 2019 Dec 10. doi: 10.1002/cncr.32655.
    PubMed     Text format     Abstract available


    November 2019
  13. PAPADIMITRAKOPOULOU VA, Han JY, Ahn MJ, Ramalingam SS, et al
    Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32503.
    PubMed     Text format     Abstract available


  14. PRINTZ C
    The number of patients with lung cancer eligible for a clinical trial could double with broader enrollment criteria.
    Cancer. 2019;125:3907.
    PubMed     Text format    


  15. HU X, Bao Y, Xu YJ, Zhu HN, et al
    Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32586.
    PubMed     Text format     Abstract available


  16. BODOR JN, Boumber Y, Borghaei H
    Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
    Cancer. 2019 Nov 6. doi: 10.1002/cncr.32468.
    PubMed     Text format     Abstract available


    October 2019
  17. LITZELMAN K, Reblin M, McDowell HE, DuBenske LL, et al
    Trajectories of social resource use among informal lung cancer caregivers.
    Cancer. 2019 Oct 18. doi: 10.1002/cncr.32545.
    PubMed     Text format     Abstract available


    September 2019
  18. WANG S, Lai S, von Itzstein MS, Yang L, et al
    Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer.
    Cancer. 2019 Sep 10. doi: 10.1002/cncr.32377.
    PubMed     Text format     Abstract available


    August 2019
  19. LIN JJ, Gainor JF
    Time to tackle the blood-brain barrier in HER2-mutant lung cancer.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32460.
    PubMed     Text format    


  20. HUO J, Hong YR, Turner K, Bian J, et al
    Utilization pattern and service settings of palliative care for patients with metastatic non-small-cell lung cancer.
    Cancer. 2019 Aug 26. doi: 10.1002/cncr.32478.
    PubMed     Text format     Abstract available


  21. FISET PO, Labbe C, Young K, Craddock KJ, et al
    Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
    Cancer. 2019 Aug 7. doi: 10.1002/cncr.32422.
    PubMed     Text format     Abstract available


  22. KHOZIN S, Miksad RA, Adami J, Boyd M, et al
    Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
    Cancer. 2019 Aug 5. doi: 10.1002/cncr.32383.
    PubMed     Text format     Abstract available


    July 2019
  23. WAN X, Luo X, Tan C, Zeng X, et al
    First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32368.
    PubMed     Text format     Abstract available


  24. CHEN Y, Zhang R, Wang L, Correa AM, et al
    Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32366.
    PubMed     Text format     Abstract available


  25. WANG H, Ou Q, Li D, Qin T, et al
    Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32372.
    PubMed     Text format     Abstract available


    April 2019
  26. MORGENSZTERN D, Ko A, O'Brien M, Ong TJ, et al
    Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.
    Cancer. 2019 Apr 1. doi: 10.1002/cncr.32114.
    PubMed     Text format     Abstract available


    March 2019
  27. PRINTZ C
    Study projects a 43% increase in lung cancer mortality among women: New research suggests that, among women, strides in reducing global deaths from breast cancer could be tempered by rising lung cancer deaths. However, according to experts, the projec
    Cancer. 2019;125:831-832.
    PubMed     Text format    


  28. GILL HS, Ramalingam SS
    A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.
    Cancer. 2019 Mar 2. doi: 10.1002/cncr.31996.
    PubMed     Text format    


  29. SINGH N, Baldi M, Kaur J, Muthu V, et al
    Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
    Cancer. 2019 Mar 2. doi: 10.1002/cncr.32028.
    PubMed     Text format     Abstract available


    February 2019
  30. BLOM EF, Ten Haaf K, Arenberg DA, de Koning HJ, et al
    Treatment capacity required for full-scale implementation of lung cancer screening in the United States.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32026.
    PubMed     Text format     Abstract available


    January 2019
  31. DELLA CORTE CM, Gay CM, Byers LA
    Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31863.
    PubMed     Text format    


  32. PRINTZ C
    Currently recommended lung cancer screening guidelines may be insufficient for high-risk minorities.
    Cancer. 2019;125:10-11.
    PubMed     Text format    


  33. PRINTZ C
    First Person: Paul Bunn, Jr, MD, FASCO: An icon in the oncology world, he has led major cancer organizations and clinical trials and launched the University of Colorado Cancer Center.
    Cancer. 2019;125:9-10.
    PubMed     Text format    


    December 2018
  34. NAZHA B, Owonikoko TK
    The clinical conundrum of managing relapsed small cell lung cancer.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31849.
    PubMed     Text format    


  35. NG TL, Liu Y, Dimou A, Patil T, et al
    Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Cancer. 2018 Dec 11. doi: 10.1002/cncr.31871.
    PubMed     Text format     Abstract available


  36. MCFARLAND DC, Shaffer K, Breitbart W, Rosenfeld B, et al
    C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31859.
    PubMed     Text format     Abstract available


  37. AHN MJ, Tsai CM, Shepherd FA, Bazhenova L, et al
    Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-Term follow-up from a pooled analysis of 2 phase 2 studies.
    Cancer. 2018 Dec 4. doi: 10.1002/cncr.31891.
    PubMed     Text format     Abstract available


    November 2018
  38. AHVENAINEN TV, Makinen NM, von Nandelstadh P, Vahteristo MEA, et al
    Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31754.
    PubMed     Text format     Abstract available


  39. MORGENSZTERN D, Cobo M, Ponce Aix S, Postmus PE, et al
    ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31779.
    PubMed     Text format     Abstract available


  40. GOLDBERG SB, Herbst RS
    Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31681.
    PubMed     Text format    


    October 2018
  41. STINCHCOMBE TE, Fan W, Schild SE, Vokes EE, et al
    A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31813.
    PubMed     Text format     Abstract available


    September 2018
  42. HATA A, Katakami N, Kaji R, Yokoyama T, et al
    Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study).
    Cancer. 2018 Sep 7. doi: 10.1002/cncr.31678.
    PubMed     Text format     Abstract available



  43. Declining lung cancer death rates lag for women in 2 US hot spots.
    Cancer. 2018;124:3467.
    PubMed     Text format    


    August 2018

  44. Neoadjuvant Nivolumab Safe, Led to Major Response Rates in Resectable Lung Cancer.
    Cancer. 2018;124:3283.
    PubMed     Text format    


    June 2018
  45. PATEL JD, Chmura SJ
    Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
    Cancer. 2018 Jun 15. doi: 10.1002/cncr.31557.
    PubMed     Text format    


    May 2018
  46. GOLDWASSER F, Vinant P, Aubry R, Rochigneux P, et al
    Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.
    Cancer. 2018 May 9. doi: 10.1002/cncr.31536.
    PubMed     Text format     Abstract available


    April 2018
  47. SPIGEL DR, Burris HA 3rd, Greco FA, Shih KC, et al
    Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31290.
    PubMed     Text format     Abstract available


  48. ARBOUR KC, Riely GJ
    Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31289.
    PubMed     Text format    


  49. PRINTZ C
    Lung cancer screening based on personal risk may save more lives.
    Cancer. 2018;124:1315.
    PubMed     Text format    


    March 2018
  50. HIRSCH FR, Sequist LV, Gore I, Mooradian M, et al
    Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31313.
    PubMed     Text format     Abstract available


    February 2018
  51. SPIGEL DR, Hainsworth JD, Joseph MJ, Shipley DL, et al
    Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.30986.
    PubMed     Text format     Abstract available


    January 2018
  52. CASSIDY RJ, Zhang X, Switchenko JM, Patel PR, et al
    Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
    Cancer. 2018 Jan 8. doi: 10.1002/cncr.31077.
    PubMed     Text format     Abstract available


    December 2017
  53. TANDBERG DJ, Tong BC, Ackerson BG, Kelsey CR, et al
    Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31196.
    PubMed     Text format     Abstract available


  54. RICHARDS TB, Henley SJ, Puckett MC, Weir HK, et al
    Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5079-5099.
    PubMed     Text format     Abstract available


  55. ASSI HI, Kamphorst AO, Moukalled NM, Ramalingam SS, et al
    Immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31105.
    PubMed     Text format     Abstract available


  56. KATAKAMI N, Uchino J, Yokoyama T, Naito T, et al
    Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
    Cancer. 2017 Dec 4. doi: 10.1002/cncr.31128.
    PubMed     Text format     Abstract available


  57. NIXON NA, Khan OF, Imam H, Tang PA, et al
    Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
    Cancer. 2017;123:4672-4679.
    PubMed     Text format     Abstract available


  58. MANSOUR MSI, Seidal T, Mager U, Baigi A, et al
    Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Cancer. 2017;125:908-917.
    PubMed     Text format     Abstract available


    November 2017
  59. HAHN EJ, Rayens MK, Wiggins AT, Gan W, et al
    Lung cancer incidence and the strength of municipal smoke-free ordinances.
    Cancer. 2017 Nov 28. doi: 10.1002/cncr.31142.
    PubMed     Text format     Abstract available


  60. SPIEGEL ML, Goldman JW, Wolf BR, Nameth DJ, et al
    Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.
    Cancer. 2017 Nov 10. doi: 10.1002/cncr.31056.
    PubMed     Text format     Abstract available


    October 2017
  61. STOY SP, Rosen L, Mueller J, Murgu S, et al
    Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.
    Cancer. 2017 Oct 20. doi: 10.1002/cncy.21941.
    PubMed     Text format     Abstract available


  62. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available


  63. HEYMANN JJ, Bulman WA, Swinarski D, Pagan CA, et al
    Programmed death-ligand 1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Cancer. 2017 Oct 12. doi: 10.1002/cncy.21937.
    PubMed     Text format     Abstract available


  64. SULLIVAN DR, Ganzini L, Lapidus JA, Hansen L, et al
    Improvements in hospice utilization among patients with advanced-stage lung cancer in an integrated health care system.
    Cancer. 2017 Oct 10. doi: 10.1002/cncr.31047.
    PubMed     Text format     Abstract available


  65. CASSIDY RJ, Zhang X, Patel PR, Shelton JW, et al
    Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cancer. 2017;123:3681-3690.
    PubMed     Text format     Abstract available


    September 2017
  66. PILLAI RN, Behera M, Owonikoko TK, Kamphorst AO, et al
    Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31043.
    PubMed     Text format     Abstract available


  67. ARBOUR KC, Kris MG, Riely GJ, Ni A, et al
    Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30990.
    PubMed     Text format     Abstract available


  68. YANG D, Zhang X, Powell CA, Ni J, et al
    Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study.
    Cancer. 2017 Sep 20. doi: 10.1002/cncr.31020.
    PubMed     Text format     Abstract available


  69. LAMBROS L, Guibourg B, Uguen A
    Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France.
    Cancer. 2017 Sep 11. doi: 10.1002/cncy.21919.
    PubMed     Text format    


  70. TRONCONE G
    Reply to Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France.
    Cancer. 2017 Sep 11. doi: 10.1002/cncy.21918.
    PubMed     Text format    


  71. PRINTZ C
    Nivolumab improves survival for patients with advanced lung cancer.
    Cancer. 2017;123:3211.
    PubMed     Text format    


  72. SADETZKI S, Chetrit A, Freedman LS, Hakak N, et al
    Cancer risk among Holocaust survivors in Israel-A nationwide study.
    Cancer. 2017;123:3335-3345.
    PubMed     Text format     Abstract available


    August 2017
  73. MOORE KN, Borghaei H, O'Malley DM, Jeong W, et al
    Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors.
    Cancer. 2017;123:3080-3087.
    PubMed     Text format     Abstract available


  74. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available


  75. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available


  76. HUNG YP, Lovitch SB, Qian X
    Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.
    Cancer. 2017;125:604-614.
    PubMed     Text format     Abstract available


  77. CAPPELLESSO R, Galasso M, Nicole L, Dabrilli P, et al
    miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cancer. 2017;125:635-643.
    PubMed     Text format     Abstract available


    July 2017
  78. PISAPIA P, Lozano MD, Vigliar E, Bellevicine C, et al
    ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Cancer. 2017 Jul 25. doi: 10.1002/cncy.21899.
    PubMed     Text format     Abstract available


  79. PILLAI RN, Behera M, Berry LD, Rossi MR, et al
    HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30869.
    PubMed     Text format     Abstract available


  80. RWIGEMA JM, Verma V, Lin L, Berman AT, et al
    Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30870.
    PubMed     Text format     Abstract available


    June 2017
  81. GOLDSTEIN DA, Bilal U, Prasad V
    Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30868.
    PubMed     Text format    


  82. GAINOR JF
    Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
    Cancer. 2017 Jun 16. doi: 10.1002/cncy.21882.
    PubMed     Text format    


  83. PRINTZ C
    Lung cancer screening rates remain very low among current and former smokers.
    Cancer. 2017;123:2189.
    PubMed     Text format    


  84. LILO MT, Allison DB, Younes BK, Cui M, et al
    The critical role of EBUS-TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings.
    Cancer. 2017 Jun 13. doi: 10.1002/cncy.21886.
    PubMed     Text format     Abstract available


  85. ZAKOWSKI MF
    Analytic inquiry: Molecular testing in lung cancer.
    Cancer. 2017;125.
    PubMed     Text format     Abstract available


  86. BAUM JE, Zhang P, Hoda RS, Geraghty B, et al
    Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Cancer. 2017;125:398-406.
    PubMed     Text format     Abstract available


    May 2017
  87. MINO-KENUDSON M
    Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.
    Cancer. 2017 May 4. doi: 10.1002/cncy.21873.
    PubMed     Text format    


  88. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    PubMed     Text format     Abstract available


  89. CHUANG JC, Neal JW
    The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30718.
    PubMed     Text format    


    April 2017
  90. ERSEK M, Miller SC, Wagner TH, Thorpe JM, et al
    Association between aggressive care and bereaved families' evaluation of end-of-life care for veterans with non-small cell lung cancer who died in Veterans Affairs facilities.
    Cancer. 2017 Apr 17. doi: 10.1002/cncr.30700.
    PubMed     Text format     Abstract available


  91. SABRA MM, Sherman EJ, Tuttle RM
    Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30690.
    PubMed     Text format     Abstract available


    March 2017
  92. ZHANG L, Jiang T, Li X, Wang Y, et al
    Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30677.
    PubMed     Text format     Abstract available


  93. SUN B, Brooks ED, Komaki RU, Liao Z, et al
    7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Cancer. 2017 Mar 27. doi: 10.1002/cncr.30693.
    PubMed     Text format     Abstract available


  94. KEAM B, Kim MK, Choi Y, Choi SJ, et al
    Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.
    Cancer. 2017;123:841-848.
    PubMed     Text format     Abstract available


    February 2017
  95. VERMA V, Shostrom VK, Kumar SS, Zhen W, et al
    Multi-institutional experience of stereotactic body radiotherapy for large (>/=5 centimeters) non-small cell lung tumors.
    Cancer. 2017;123:688-696.
    PubMed     Text format     Abstract available


  96. SAAB J, Hoda RS, Narula N, Hoda SA, et al
    Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens.
    Cancer. 2017;125:128-137.
    PubMed     Text format     Abstract available


  97. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    PubMed     Text format     Abstract available


    January 2017
  98. VELIZHEVA NP, Rechsteiner MP, Wong CE, Zhong Q, et al
    Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
    Cancer. 2017;125:30-40.
    PubMed     Text format     Abstract available


    December 2016
  99. BISHOP JA, French CA, Ali SZ
    Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.
    Cancer. 2016;124:901-908.
    PubMed     Text format     Abstract available


    June 2016
  100. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: